H1-antihistamine therapy

Novartis has announced that the European Commission ( EC ) has approved the use of Xolair ( Omalizumab ) as...


Many patients with chronic idiopathic urticaria ( also called chronic spontaneous urticaria ) do not have a response to therapy...